<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01950221</url>
  </required_header>
  <id_info>
    <org_study_id>11-002413</org_study_id>
    <nct_id>NCT01950221</nct_id>
    <nct_alias>NCT01571193</nct_alias>
  </id_info>
  <brief_title>Pomegranate Extract and Memory</brief_title>
  <official_title>12-Month, Double-blind, Placebo-Controlled Study of Pomegranate Extract</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>POM Wonderful LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project is designed to study whether pomegranate extract benefits cognitive abilities in&#xD;
      middle-aged and older non-demented volunteers. Subjects will be randomly assigned to one of&#xD;
      two treatment groups: either a placebo or the pomegranate extract supplement. Both the&#xD;
      placebo and pomegranate extract will be packaged in 1000 milligram capsules to maintain&#xD;
      blindness. Subjects will take one 1000 milligram capsule daily for twelve months.&#xD;
&#xD;
      The investigators expect the people receiving the pomegranate extract supplement to show&#xD;
      better cognitive performance compared with those receiving a placebo after one, six, and&#xD;
      twelve months. The investigators believe cognitive decline and treatment response will vary&#xD;
      according to a genetic risk for Alzheimer's.&#xD;
&#xD;
      The investigators will study 212 non-demented subjects aged 50-75 years. Initially, subjects&#xD;
      will undergo a clinical assessment, an MRI and a blood draw to determine genetic risk and to&#xD;
      rule out other neurodegenerative disorders linked to memory complaints.&#xD;
&#xD;
      Subsequently, subjects will undergo the first memory (or neuropsychological) assessments.&#xD;
      Following the first assessment, subjects will begin taking the supplement (either the&#xD;
      pomegranate extract or the placebo). Subjects will undergo a brief memory test at one-month&#xD;
      mark. At six months, subjects will have a second, full neuropsychological assessment. The&#xD;
      final assessment will take place at the end of the study, the 12-month mark. Additional blood&#xD;
      will be drawn at baseline and at 12 months and frozen to assess inflammatory markers if&#xD;
      outcomes are positive. Subjects will also be asked to come to the University of California,&#xD;
      Los Angeles (UCLA) at 3 and 9 months for supplement refills.&#xD;
&#xD;
      In total, subjects will be expected to come to UCLA for 7 visits during the course of 12-13&#xD;
      months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improved cognitive performance</measure>
    <time_frame>1 year</time_frame>
    <description>Non-demented volunteers aged 50-75 who receive a daily dietary supplement of pomegranate extract will show improved cognitive performance compared to baseline versus those receiving a placebo after one, six, and twelve months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive performance improvement and genotype</measure>
    <time_frame>1 year</time_frame>
    <description>Cognitive change in the pomegranate intervention group will vary according to genotype.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">212</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>POMx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>POMx is a 1,000 milligram capsule of natural pomegranate polyphenol extract.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Composition of the Drug Placebo Component/Function/Weight/Percentage of Fill Weight = Cellulose/Bulk agent/658 mg/64.5% Caramel/Colorant/79mg/7.8% Beet root/Flavor Ingredient/263mg/25.8% Magnesium stearate/USP Lubricant/10mg/1.0% Silica Dioxide/FCC Glidant/10mg/1.0% Total = 1020 mg/100% The method of manufacture of the placebo is identical to that of the drug product, except cellulose, caramel, and beet root are added in place of the active ingredient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>POMx</intervention_name>
    <description>&quot;POMx&quot; is a 1,000 milligram capsule of natural pomegranate polyphenol extract.</description>
    <arm_group_label>POMx</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Agreement to participate in the 12-month double-blind, placebo-controlled clinical&#xD;
             trial of pomegranate extract.&#xD;
&#xD;
          -  Nondemented subjects either those with normal cognition or with Mild Cognitive&#xD;
             Impairment will be included.&#xD;
&#xD;
          -  Age 50 to 75 years.&#xD;
&#xD;
          -  No significant cerebrovascular disease: modified Ischemic Score of &lt; 4&#xD;
&#xD;
          -  Adequate visual and auditory acuity to allow neuropsychological testing.&#xD;
&#xD;
          -  Screening laboratory tests and EKG without significant abnormalities that might&#xD;
             interfere with the study. If screening laboratory tests or EKG show abnormalities,&#xD;
             subject must obtain written clearance from primary care physician before continuing in&#xD;
             the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of probable Alzheimer's disease (AD) or any other dementia (e.g., vascular,&#xD;
             Lewy body, frontotemporal) (McKhann et al, 1984). Evidence of other neurological or&#xD;
             physical illness that can produce cognitive deterioration. Volunteers with a history&#xD;
             of stroke, Transient Ischemic Attack (TIA), carotid bruits, or lacunes on MRI scans&#xD;
             will be excluded. Determination of dementia will be based on the clinical evaluation&#xD;
             including assessment of functional abilities, and cognitive screening.&#xD;
&#xD;
          -  Contraindication to the MRI including claustrophobia, metal in body, surgery within 60&#xD;
             days, certain implants or previous abnormal MRI results.&#xD;
&#xD;
          -  Evidence of Parkinson's disease as determined by the motor examination (items 18-31)&#xD;
             of the Unified Parkinson's Disease Rating Scale (Fahn et al, 1987).&#xD;
&#xD;
          -  History of myocardial infarction within the previous year, or unstable cardiac&#xD;
             disease.&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic BP &gt; 170 or diastolic BP &gt; 100).&#xD;
&#xD;
          -  History of significant liver disease, clinically-significant pulmonary disease, or&#xD;
             diabetes.&#xD;
&#xD;
          -  Current diagnosis of any major psychiatric disorder&#xD;
&#xD;
          -  Current diagnosis or history of alcoholism or substance addiction.&#xD;
&#xD;
          -  Regular use of any medication that may affect cognitive functioning including:&#xD;
             centrally active beta-blockers, narcotics, Clonidine, anti-Parkinsonian medications,&#xD;
             antipsychotics, systemic corticosteroids, medications with significant cholinergic or&#xD;
             anticholinergic effects, anti-convulsants, or Warfarin.&#xD;
&#xD;
          -  Occasional use of anxiety or sleeping medications known to cause cognitive dulling&#xD;
             will be allowed, but discouraged: chloral hydrate, non-benzodiazepine hypnotics such&#xD;
             as: Ambien (Zolpidem) and Lunesta; or benzodiazepines such as Ativan (Lorazepam),&#xD;
             Xanax (Alprazolam), Klonopin (Clonazepam), and Restoril (Temazepam).&#xD;
&#xD;
          -  Use of any of the following medications: Amitriptyline, Amiodarone, Desipramine,&#xD;
             Fenofibrate, Flecainide, Fluconazole, Fluoxetine, Fluvastatin, Fluvoxamine, Isoniazid,&#xD;
             Lovastatin, Ondansetron, Phenylbutazone, Probenecid, Sertraline, Sulfamethoxazole,&#xD;
             Sulfaphenazole, Teniposide, Voriconazole, Warfarin, and Zafirlukast&#xD;
&#xD;
          -  Use of cognitive enhancing supplements (e.g. Ginkgo biloba).&#xD;
&#xD;
          -  Use of any supplement containing pomegranate or pomegranate juice.&#xD;
&#xD;
          -  Use of any investigational drugs within the previous month or longer, depending on&#xD;
             drug half-life.&#xD;
&#xD;
          -  Pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCLA Longevity Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.semel.ucla.edu/longevity</url>
    <description>UCLA Longevity Center</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 16, 2013</study_first_submitted>
  <study_first_submitted_qc>September 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2013</study_first_posted>
  <last_update_submitted>February 28, 2020</last_update_submitted>
  <last_update_submitted_qc>February 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Gary Small, MD</investigator_full_name>
    <investigator_title>Professor of Psychiatry and Biobehavioral Sciences</investigator_title>
  </responsible_party>
  <keyword>Double-blind Trial</keyword>
  <keyword>Placebo-controlled</keyword>
  <keyword>Pomegranate</keyword>
  <keyword>Memory</keyword>
  <keyword>Memory Impairment</keyword>
  <keyword>Cognition</keyword>
  <keyword>Ages 50-75</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

